

Microbicide Trials Network

CLARIFICATION MEMO #02 TO:

MTN-034

A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

DAIDS Protocol #: 12066

IND#: 139,598

Version 2.0 / 7 December 2017

Clarification Memo Date: 27 May 2020

Section 1: Summary of Clarifications and Rationale

The procedures clarified in this Clarification Memorandum (CM) have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. IRB/IEC approval of this CM is not required by the sponsor; however, investigators may submit the CM to the IRB/IEC overseeing the study at their site for information. This CM is official MTN-034 documentation and is effective immediately. A copy of this CM must be retained in each study site's Essential Documents file for MTN-034. No change in informed consent is necessitated by or included in this CM.

This document includes information related to COVID-19's impact on study implementation. This document clarifies that the content of the planned behavioral assessments may include questions related to the impact of the COVID-19 pandemic on the context of participants' HIV prevention and study product use. This document also clarifies that the overall study duration at study sites may be affected by COVID-19 closures, and that changes to procedures may be implemented to mitigate potential hazards to participants or due to public health emergencies at the study sites. This document also updates RTI International's address and the Protocol Team Roster.

Section 2: Implementation

With the exception of updates to the protocol team roster, text to be deleted is noted below with a ~~strikethrough~~, text to be added is in **bold**, and text in **bold italics** is not to be added, but to serve as a clarification of the implementation item in question. This information will be included in the protocol the next time the protocol is updated.

1.) The following clarification applies to Section 7.7, *Behavioral Evaluations*:

At Enrollment (for new participants) or at their next scheduled study visit (for already enrolled participants) and at one or more timepoints during the study, additional questions may be asked related to COVID-19's potential influence on the context of participants' HIV prevention and study product use, in order to explore the impact of the pandemic on study product adherence, acceptability, and preference.

2.) The following clarification applies to Protocol Summary, *Study Duration*, Section 4.4., *Time to Complete Accrual*; and Section 10.5, *Participant Accrual, Follow-up and Retention*:

Overall study duration - from first enrollment through closure of all follow-up - may be longer than planned if temporary site closures due to the COVID-19 pandemic cause delays or pauses in enrolling participants at one or more research sites.

3.) The following clarification applies to Section 13, *Human Subjects Protections*:

Changes to this protocol may be implemented by investigators prior to IRB/IEC approval, if those changes are required to eliminate apparent immediate hazards to the study participant. [See 45 CFR 46.108(a)(3)(iii) under the 2018 Requirements and 45 CFR 46.103(b)(4)(iii) under the pre-2018 Requirements.] These changes must

be documented as Protocol Deviations and reported to the Protocol Team and IRB/IEC as soon as possible. [See ICH E6(R2), Good Clinical Practice, Section 4.5.4.] In the event of a public health emergency, investigators should adhere to the recommendations of their local institutions, IRB/IEC and local health departments. When conflicts exist between local directives, MTN, Protocol Team and/or DAIDS policies or guidance, sites should follow the requirement that is most protective of study participants and site staff. [See DAIDS Guidance, Coronavirus Disease (COVID-19) and DAIDS HIV/AIDS Network Clinical Research Studies, Page 3, dated March 13, 2020.]

4.) Section 1.5, *Data Centers*:

Women's Global Health Imperative Program
RTI International
~~351 California Street, Suite 500~~
~~San Francisco, CA 94104 USA~~
2150 Shattuck Avenue, Suite 800
Berkeley, CA 94704 USA

5.) Protocol Team Roster – Deletions: Karen Patterson, Barbra Richardson.

6.) Protocol Team Roster – Updates:

Thesla Palanee-Phillips, M Med Sci, PhD, M Sc
Site Investigator of Record
Wits RHI
Research Centre
7 Esselen Street, Hillbrow
Johannesburg, 2001 South Africa
Phone: 27-11-358-5471
~~Fax: 27-86-554-1093~~
Email: tpalanee@whri.ac.za

Mary Kate Shapley-Quinn, MPH
Project Coordinator and Data Manager
Women's Global Health Imperative Program
RTI International
~~351 California Street, Suite 500~~
~~San Francisco, CA 94104 USA~~
2150 Shattuck Avenue, Suite 800
Berkeley, CA 94704 USA
Phone: 415-848-1316
Email: mshapley@rti.org

Kim Woodhouse
Program Manager
Women's Global Health Imperative Program
RTI International
~~351 California Street, Suite 500~~
~~San Francisco, CA 94104 USA~~
2150 Shattuck Avenue, Suite 800
Berkeley, CA 94704 USA
Phone: 415-848-1344
Fax: 415-848-1330
Email: kwoodhouse@rti.org

Sarah T. Roberts, PhD
Research Analyst
Women's Global Health Imperative Program
RTI International
~~351 California Street, Suite 500~~
~~San Francisco, CA 94104 USA~~
2150 Shattuck Avenue, Suite 800

Berkeley, CA 94704 USA

Phone: 415-848-1335

Email: sroberts@rti.org

Ariane van der Straten, PhD, MPH
QDMC Director and BRWG Co-representative
Women's Global Health Imperative Program
RTI International

~~351 California Street, Suite 500~~

~~San Francisco, CA 94104 USA~~

2150 Shattuck Avenue, Suite 800

Berkeley, CA 94704 USA

Phone: 415-848-1324

Fax: 415-848-1330

Email: ariane@rti.org

7.) Protocol Team Roster – Additions:

Elizabeth Brown, ScD

SDMC Principal Investigator

FHCRC – SCHARP

1100 Fairview Avenue North, M2-C200

PO Box 19024

Seattle, WA 98109-1024 USA

Phone: 206-667-1731

Fax: 206-667-4812

Email: erbrown@fhcrc.org

The above information will be incorporated into the next version of the protocol at a later time if it is amended.